Navigation Links
Alba Therapeutics Announces Phase IIb Clinical Trial for Oral AT-1001 for the Treatment of Celiac Disease
Date:9/19/2007

g evaluated for the treatment of Type 1 Diabetes and Crohn's Disease. Results of the Company's first study in celiac patients are available online at:

http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2036.2007.03413 .x

About Alba

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical company based in Baltimore, Maryland. Alba is dedicated to development and commercialization of disease-modifying therapeutics to treat autoimmune and inflammatory disease, drug delivery agents and mucosal vaccine adjuvants by exploiting its technology to regulate the assembly and disassembly of tight junctions in cell barriers throughout the body.

Contact: Bernard McDonald, PhD

Phone: 410-319-0780

E-mail: info@albatherapeutics.com

Web site: http://www.albatherapeutics.com


'/>"/>
SOURCE Alba Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)...wswire/ -- Milk. It does a body good. And,now it,...ter years of,research, scientists at OncoNutritio...k that stimulate the body,s own production of anti... Release, go to:, http://www.prnewswire.com/mnr/eq...w cancer therapies, the chief scientist, Dr. David...
(Date:11/20/2008)...swire/ -- Radius Health ("Radius") announced today...ts second institutional financing round, increasin...he total amount raised since the company,s incepti...nvestors participated in the financing, led by MPM...al, The Wellcome Trust, HealthCare Ventures, Oxfor...
(Date:11/20/2008)... The Scandinavian-based drug,devel...ts of studies on its,lead antimicrobial candidate...he studies showed that the novel lytic peptidomime...ificantly better towards killing Staphylococcus,a...d standard drugs. In,addition to this it has prov...
(Date:11/19/2008)...e statistical significance , , ISELIN, N.J....ration (Nasdaq: PARS ) today announced results f...oEmulsion (NE) drug delivery technology formulated... multi-center, randomized, double-blinded, placebo...y of the Company,s 3% Diclofenac Diethanolamine Na...
Breaking Medicine Technology:Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects 2Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Experimental Drug Fights Prostate Cancer 5747 1Experimental Drug Fights Prostate Cancer 5747 2Tweens double use of diabetes drugs 5745 1Tweens double use of diabetes drugs 5745 2Higher levels of pollutants found in fish caught near a coal fired power plant 5743 1Higher levels of pollutants found in fish caught near a coal fired power plant 5743 2HCA Reports Third Quarter 2007 Results 5741 1HCA Reports Third Quarter 2007 Results 5741 2HCA Reports Third Quarter 2007 Results 5741 3HCA Reports Third Quarter 2007 Results 5741 4HCA Reports Third Quarter 2007 Results 5741 5HCA Reports Third Quarter 2007 Results 5741 6HCA Reports Third Quarter 2007 Results 5741 7HCA Reports Third Quarter 2007 Results 5741 8HCA Reports Third Quarter 2007 Results 5741 9HCA Reports Third Quarter 2007 Results 5741 10HCA Reports Third Quarter 2007 Results 5741 11HCA Reports Third Quarter 2007 Results 5741 12HCA Reports Third Quarter 2007 Results 5741 13HCA Reports Third Quarter 2007 Results 5741 14
...NESS WIRE)--Mar 20, 2007 - Arrowhead,Research Corp...y-owned subsidiary Calando Pharmaceuticals has pub...Academy of Sciences,(PNAS) of the first non-human ...h Calando,s lead siRNA therapeutic candidate., Cal...eted,polymeric delivery systems and siRNA design t...
...20, 2007 /PRNewswire/ -- Treatment of,coronary art... the,inpatient setting, according to a study publi..., U.S. hospitalization rates for heart attacks (ac...from 2002 to 2005, possibly due,to broader use of ...irin, as well as declines in risk factors like smo...
Other Medicine Technology:Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA 2Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA 3Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 2Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 3
(Date:11/21/2008)... The Providence Service,...t Craig A. Norris, the Company,s,Chief Operating ... of,Directors. Mr. Norris, appointment fills the...even I. Geringer and returns the board to six memb...of the Board. , Mr. Norris, age 41, has bee...
(Date:11/21/2008)...roved effective against Lennox-Gastaut syndrome ,...new drug called Banzel (rufinamide) has been appro... of epilepsy called Lennox-Gastaut syndrome, the U... , The approval was based on results of a four-... to 30. Compared to patients who took a placebo, t...
(Date:11/21/2008).... 21 New research at W...okeless, spitless tobacco product aimed at young a...nd that RJ Reynolds, Camel Snus - touted as a soci...s surprisingly high levels of nicotine. , , ...r snuff products," said Bruce Adkins of the state ...
(Date:11/21/2008)...1 U.S. News & World...urance (NCQA) ranked BlueChoice(R) HealthPlan of S...ealth Plans(TM), published in U.S. News & Worl...ed annual ranking ranks the nation,s best health p...n and NCQA accreditation scores. NCQA and U.S. New...
Breaking Medicine News(10 mins):Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2
...esticides and solvents can further lower fertility...udy shows these chemicals may worsen the effect of...infertility. The authors stress the findings shoul... involved a selected population of infertile men, ...
...communication has always been an effective utility...eo disc is helping patients make important decisio...ld you what treatment to have are long gone. Patie...aking process.// But sometimes this is difficult, ...
...e era where one fights battle towards eternity and...ality and morbidity indicators preclude the exista... result of such on going research , Dr. Simona Gia... Sanita, Rome, and colleagues from the MATISS Proj...
...orks better than massage as a treatment for chroni...ther therapies when used over long periods.That's ...into the effectiveness of the complementary medici... needles into special sites in the nervous system....
Other Medicine News:
CleanBox DNA workstation with two 254nm UV lambs & 12-hr timer, 90cm (36-inch)width, single door, 115V (w/crating)
...ing of tube racks. Its camera-based vision system ... per rack, making it ideal for use in automated se... rack to be read automatically and can be easily a...prevents a rack from being read in the wrong orien...
Polypropylene workbench top with powder-coated steel legs. Height is adjustable from 25"-34". Available in hundreds of sizes and configurations. Accessories include shelves, drawers, light fixtures a
Perforated or Rod Top, Free Standing or Wall Mounted, Storage Cubby Optional, Polypropylene Construction
Medicine Products: